Advanced Enzyme Technologies Ltd (ADVENZYMES)

📊 Quarterly Results (₹ Cr)

Quarterly revenue shows a sequential decline to ₹190 million in June 2026 from ₹203 million in March 2026, with operating profit margin compressing to 21.6% from 26.1%, reflecting pressure on core operations despite international growth. However, PAT and EPS remain relatively stable due to cost management, while international revenue now constitutes 51% of total sales, up from 49% domestically — a strategic shift toward higher-growth global markets in human nutrition and probiotics.

🔮 Management Outlook & What's Next

Management has explicitly highlighted expansion in Human Nutrition via the Wellfa nutraceutical brand and ongoing probiotic development as key growth drivers, particularly in international markets where revenue grew 9% YoY to ₹961 million in Q1 FY27. They attribute margin pressure to temporary factors but emphasize that the strategic shift toward specialty ingredients and global markets positions the company for long-term value creation, supported by disciplined capital allocation and shareholder-friendly initiatives like buybacks.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet remains extremely conservative, with negligible debt (₹21 million borrowings as of March 2026) and strong equity reserves (₹1,609 million), enabling funding of buybacks entirely from internal reserves and securities premium without leverage. Total assets have grown steadily to ₹1,839 million, reflecting investments in capacity and R&D, while reserves increased from ₹1,398 million to ₹1,609 million, underscoring financial resilience and capacity for sustained shareholder returns.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding remains stable at ~43.2%, but institutional investor interest is rising — FII allocation increased from 25.41% in Q2FY26 to 26.71% in Q1FY27, while DII declined slightly from 6.41% to 4.78%. The growing FII presence suggests increasing institutional confidence, possibly driven by the buyback signal and international growth narrative, while the expanding retail shareholder base (63,599 investors) indicates broad-based interest in the company's transformation.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1) International revenue growth (now 51% of sales) is offset by sequential revenue declines and margin compression in core operations, indicating execution risk in transitioning to new growth engines. 2) EBITDA margin has declined to 27% from 31% YoY, reflecting pricing pressure or input cost inflation in the core business despite management's optimism about specialty segments. 3) The company's reliance on buybacks for shareholder returns is constrained by regulatory limits and may not be sustainable if international expansion fails to deliver consistent profitability.

📋 Recent Filings

• 🟡 Board Meeting2026-09-29Advanced Enzyme Technologies Ltd disclosed a revised request from promoter Radhika Ashish Pujara to reclassify her from the Promoter Group to Public c…
• 🟡 buyback redemption2026-09-29Advanced Enzyme Technologies repurchased 25,000 shares on September 29, 2026 at an average price of ₹283.60 per share through Emkay Global, bringing t…
• Announcement2026-09-28Advanced Enzyme Technologies Ltd announced that its trading window will close on October 1, 2026, remaining shut until 48 hours after the September 30…
• 🟡 buyback redemption2026-09-22Advanced Enzyme Technologies repurchased 1,136 shares on September 22, 2026 at an average price of ₹295.90 per share through Emkay Global, bringing th…
• 🟡 buyback redemption2026-09-21Advanced Enzyme Technologies repurchased 50,000 shares at an average price of **₹289.49** on September 21, 2026, bringing the cumulative buyback to **…
• 🟡 buyback redemption2026-09-18Advanced Enzyme Technologies repurchased 14,08,904 equity shares at an average price of ₹288.92 per share on September 18, 2026, adding to its cumulat…
• 🟡 buyback redemption2026-09-17Advanced Enzyme Technologies repurchased 56,066 shares on September 17, 2026 at an average price of ₹289.48 per share through Emkay Global, bringing t…
• 🟡 Board Meeting2026-09-17Advanced Enzyme Technologies Ltd disclosed revised requests from four promoter group members—Savita Chandrakumar Rathi, Piyush Chandrakumar Rathi, Adv…
• 🟡 buyback redemption2026-09-16Advanced Enzyme Technologies repurchased 55,665 shares on September 16, 2026 at an average price of ₹291.25 per share through Emkay Global, bringing t…
• 🟡 buyback redemption2026-09-15

🧠 Analyst's Read

The company is in a strategic inflection point, shifting from domestic commodity-like chemical sales toward international specialty nutrition and probiotics, supported by disciplined capital allocation and buybacks. While near-term margin pressure persists, the trajectory hinges on successful commercialization of Wellfa and probiotic products in global markets — making international revenue trends and margin recovery the critical watchpoints for future performance.

Based on filing content and financial data. Not a recommendation.